386 related articles for article (PubMed ID: 26718027)
1. Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.
Li Z; Li Q; Han L; Tian N; Liang Q; Li Y; Zhao X; Du C; Tian Y
Oncol Rep; 2016 Feb; 35(2):1013-9. PubMed ID: 26718027
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of splice-switching oligonucleotides.
Bauman JA; Li SD; Yang A; Huang L; Kole R
Nucleic Acids Res; 2010 Dec; 38(22):8348-56. PubMed ID: 20719743
[TBL] [Abstract][Full Text] [Related]
3. Modulation of RNA splicing as a potential treatment for cancer.
Bauman JA; Kole R
Bioeng Bugs; 2011; 2(3):125-8. PubMed ID: 21637003
[TBL] [Abstract][Full Text] [Related]
4. Modification of BCLX pre-mRNA splicing has antitumor efficacy alone or in combination with radiotherapy in human glioblastoma cells.
Dou Z; Lei H; Su W; Zhang T; Chen X; Yu B; Zhen X; Si J; Sun C; Zhang H; Di C
Cell Death Dis; 2024 Feb; 15(2):160. PubMed ID: 38383492
[TBL] [Abstract][Full Text] [Related]
5. The importance of Bcl-xL in the survival of human RPE cells.
Zhang N; Peairs JJ; Yang P; Tyrrell J; Roberts J; Kole R; Jaffe GJ
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3846-53. PubMed ID: 17652760
[TBL] [Abstract][Full Text] [Related]
6. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.
Taylor JK; Zhang QQ; Wyatt JR; Dean NM
Nat Biotechnol; 1999 Nov; 17(11):1097-100. PubMed ID: 10545916
[TBL] [Abstract][Full Text] [Related]
7. Modification of alternative splicing of Bcl-x pre-mRNA in bladder cancer cells.
Zhu Z; Xing S; Cheng P; Zeng F; Lu G
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(2):213-6. PubMed ID: 16850750
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel cis-element that regulates alternative splicing of Bcl-x pre-mRNA.
Lee J; Zhou J; Zheng X; Cho S; Moon H; Loh TJ; Jo K; Shen H
Biochem Biophys Res Commun; 2012 Apr; 420(2):467-72. PubMed ID: 22440396
[TBL] [Abstract][Full Text] [Related]
9. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
Mercatante DR; Mohler JL; Kole R
J Biol Chem; 2002 Dec; 277(51):49374-82. PubMed ID: 12381725
[TBL] [Abstract][Full Text] [Related]
10. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
[TBL] [Abstract][Full Text] [Related]
11. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death.
Mercatante DR; Bortner CD; Cidlowski JA; Kole R
J Biol Chem; 2001 May; 276(19):16411-7. PubMed ID: 11278482
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
[TBL] [Abstract][Full Text] [Related]
13. Chimeric peptide nucleic acid compounds modulate splicing of the bcl-x gene in vitro and in vivo.
Wilusz JE; Devanney SC; Caputi M
Nucleic Acids Res; 2005; 33(20):6547-54. PubMed ID: 16299354
[TBL] [Abstract][Full Text] [Related]
14. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
16. Aberrant alternative splicing pattern of ADAR2 downregulates adenosine-to-inosine editing in glioma.
Li Z; Tian Y; Tian N; Zhao X; Du C; Han L; Zhang H
Oncol Rep; 2015 Jun; 33(6):2845-52. PubMed ID: 25873329
[TBL] [Abstract][Full Text] [Related]
17. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
18. Antisense-mediated exon skipping to shift alternative splicing to treat cancer.
Wan J
Methods Mol Biol; 2012; 867():201-8. PubMed ID: 22454063
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
[TBL] [Abstract][Full Text] [Related]
20. Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.
Resina S; Kole R; Travo A; Lebleu B; Thierry AR
J Gene Med; 2007 Jun; 9(6):498-510. PubMed ID: 17471591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
